{"success":true,"data":{"pressRelease":{"id":"45526","rtpr_id":"nNFC3xrDXs","ticker":"ALDX","exchange":"NASDAQ","all_tickers":["ALDX"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","published_at":"2026-05-26T16:00:13.689Z","article_body":"New York, New York--(Newsfile Corp. - May 26, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Aldeyra Therapeutics, Inc.\n(NASDAQ: ALDX) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aldeyra securities between\nNovember 3, 2023 and March 16, 2026, both dates inclusive (the \"Class\nPeriod\"). Such investors are encouraged to join this case by visiting the\nfirm's site: bgandg.com/ALDX\n(https://api.newsfilecorp.com/redirect/bgO3as1qP7).\n\nAldeyra Case Details\n\nThe Complaint alleges that Defendants throughout the Class Period made false\nand/or misleading statements and/or failed to disclose that:\n1. The results of the reproxalap (an Aldeyra drug candidate) clinical trials\nwere inconsistent;\n2. the inconsistency of the results rendered any purported positive findings\nfrom these trials unreliable and not meaningful; and\n3. as a result, defendants' statements about Aldeyra's business, operations,\nand prospects were materially false and misleading and/or lacked a reasonable\nbasis at all relevant times.\nWhat's Next for Aldeyra Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/ALDX\n(https://api.newsfilecorp.com/redirect/3KQwBIew2D), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Aldeyra you\nhave until May 29, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Aldeyra Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aldeyra Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/XEvRaTMoNv), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/DOvMxcPkWk), X\n(https://api.newsfilecorp.com/redirect/rpgKJSwEJe), Facebook\n(https://api.newsfilecorp.com/redirect/Vv4R2SMaxA), or Instagram\n(https://api.newsfilecorp.com/redirect/zAn3oHje7k).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/294922","article_body_html":"","raw_payload":{"data":{"id":"nNFC3xrDXs","title":"Bronstein, Gewirtz & Grossman LLC Urges Aldeyra Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","ticker":"ALDX","created":"2026-05-26T16:00:13.689Z","tickers":["ALDX"],"exchange":"NASDAQ","article_body":"New York, New York--(Newsfile Corp. - May 26, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against Aldeyra Therapeutics, Inc.\n(NASDAQ: ALDX) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Aldeyra securities between\nNovember 3, 2023 and March 16, 2026, both dates inclusive (the \"Class\nPeriod\"). Such investors are encouraged to join this case by visiting the\nfirm's site: bgandg.com/ALDX\n(https://api.newsfilecorp.com/redirect/bgO3as1qP7).\n\nAldeyra Case Details\n\nThe Complaint alleges that Defendants throughout the Class Period made false\nand/or misleading statements and/or failed to disclose that:\n1. The results of the reproxalap (an Aldeyra drug candidate) clinical trials\nwere inconsistent;\n2. the inconsistency of the results rendered any purported positive findings\nfrom these trials unreliable and not meaningful; and\n3. as a result, defendants' statements about Aldeyra's business, operations,\nand prospects were materially false and misleading and/or lacked a reasonable\nbasis at all relevant times.\nWhat's Next for Aldeyra Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/ALDX\n(https://api.newsfilecorp.com/redirect/3KQwBIew2D), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Aldeyra you\nhave until May 29, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to Aldeyra Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Aldeyra Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/XEvRaTMoNv), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/DOvMxcPkWk), X\n(https://api.newsfilecorp.com/redirect/rpgKJSwEJe), Facebook\n(https://api.newsfilecorp.com/redirect/Vv4R2SMaxA), or Instagram\n(https://api.newsfilecorp.com/redirect/zAn3oHje7k).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/294922"},"type":"article","timestamp":"2026-05-26T16:00:13.738510896Z","server_sent_at_ms":1779811213738},"received_at":"2026-05-26T16:00:13.807Z","source_url":"https://www.newsfilecorp.com/release/294922"},"analysis":{"id":"34959","press_release_id":"45526","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman LLC issued a press release announcing a class action lawsuit filed against Aldeyra Therapeutics and certain officers.\n\nThe complaint alleges false or misleading statements regarding inconsistent clinical trial results for the drug candidate reproxalap during the class period of November 3, 2023, to March 16, 2026.\n\nThe release solicits investors with losses to contact the firm and notes a May 29, 2026, deadline to request appointment as lead plaintiff.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"}],"products":["reproxalap"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman LLC. The release is marketing for the firm, not an issuer disclosure. No certified class or settlement announced."},"tickerRelevance":{"others":[],"primary":"ALDX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman LLC issued a press release announcing a class action lawsuit filed against Aldeyra Therapeutics and certain officers.\n\nThe complaint alleges false or misleading statements regarding inconsistent clinical trial results for the drug candidate reproxalap during the class period of November 3, 2023, to March 16, 2026.\n\nThe release solicits investors with losses to contact the firm and notes a May 29, 2026, deadline to request appointment as lead plaintiff.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"}],"products":["reproxalap"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-26T16:04:14.017Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":27612,"modelName":"george-droid-qwen-72b"}}